The repeal of the “X-waiver” in the Consolidated Appropriations Act of 2023 was widely celebrated as a long-overdue step toward expanding access to buprenorphine for opioid use disorder (OUD). By removing the requirement for supplemental training and a special DEA designation, policymakers hoped to normalize treatment and reduce barriers for clinicians. Yet nearly two years
Why buprenorphine prescribing still lags after the X-waiver repeal originally appeared in KevinMD.com.
Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.